Kinetics of HCV viremia in kidney transplant recipients during and after alpha-interferon therapy
| Autor: | Jacques Izopet, Dominique Durand, Martine Dubois, Michel Duffaut, Michèle Cazabat, Jean-Paul Charlet, Lionel Rostaing, Chalom Sayada, Hugues Ton-That, J. Puel |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male Hepatitis C virus medicine.medical_treatment Alpha interferon Viremia Hepacivirus Interferon alpha-2 medicine.disease_cause Antiviral Agents Polymerase Chain Reaction Interferon medicine Humans Longitudinal Studies Interferon alfa Aged business.industry Interferon-alpha Immunosuppression Alanine Transaminase Hepatitis C Antibodies Middle Aged medicine.disease Prognosis Hepatitis C Kidney Transplantation digestive system diseases Recombinant Proteins Transplantation Immunoglobulin M Nephrology Immunology Chronic Disease RNA Viral Female business medicine.drug Kidney disease |
| Zdroj: | American journal of nephrology. 17(5) |
| ISSN: | 0250-8095 |
| Popis: | Fifteen kidney transplant recipients with chronic hepatitis C were given 3 million units recombinant α 2b -interferon for 142 ± 35 days. There were significant decreases in hepatitis C virus (HCV) RNA 1 month after the initiation of treatment (p < 0.01), and at the end of treatment (p < 0.05). HCV RNA was undetectable by PCR analysis during treatment in 5 patients. But HCV RNA reappeared in all patients 1 month after the cessation of therapy, and the level of viremia returned to baseline. While all patients had normalized alanine aminotransferase (ALT) activities at the end of therapy, 11 experienced a relapse during the follow-up period (1 year). There was a correlation between the amount of HCV RNA at the end of treatment and the time of relapse. Serum IgM against core protein of HCV were detected in 7/15 patients. Anti-core IgM remained detectable during treatment and afterwards. There was no correlation between IgM status and other virological parameters, or ALT activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|